Newly developed anti-angiogenic therapy in non-small cell lung cancer.

Related Articles

Newly developed anti-angiogenic therapy in non-small cell lung cancer.

Oncotarget. 2018 Feb 09;9(11):10147-10163

Authors: Qu J, Zhang Y, Chen X, Yang H, Zhou C, Yang N

Abstract
Angiogenesis and its role in the growth and development of non-small cell lung cancer (NSCLC) metastases has become an increasing clinical problem. Vascular endothelial growth factor (VEGF) plays a key role in advanced NSCLC. To some extent, anti-angiogenic therapies acquired some efficacy in combination with chemotherapy, target therapy and immunotherapy. However, the reliable clinical benefit obtained with these drugs is still questionable and often quantitatively limited. In this review, the authors highlight the data obtained from first-line, second-line, epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) target therapy and immunotherapy in NSCLC patients who are treated with anti-angiogenic molecules in advanced NSCLC. The purpose of this study is to help us truly understand how to best use angiogenesis therapy in advanced NSCLC.

PMID: 29515799 [PubMed]

http://ift.tt/2oZNT8I